Image 1 of 1
Image 1 of 1
Image 1 of 1
Image 1 of 1
(LY3437943) is a novel triple-agonist peptide targeting GLP-1, GIP, and glucagon receptors simultaneously, engineered with a fatty-acid moiety for an approximately 6 day half-life and once-weekly dosing. Phase 2 trials demonstrated up to 24% body weight reduction at 48 weeks and HbA1c reductions of 1.3 to 2.0% in type 2 diabetes patients. Not FDA-approved; available for research use only.
This product is intended strictly for laboratory research purposes only. It is not approved for human or animal use and must not be used in food, supplements, pharmaceuticals, or cosmetic applications.
(LY3437943) is a novel triple-agonist peptide targeting GLP-1, GIP, and glucagon receptors simultaneously, engineered with a fatty-acid moiety for an approximately 6 day half-life and once-weekly dosing. Phase 2 trials demonstrated up to 24% body weight reduction at 48 weeks and HbA1c reductions of 1.3 to 2.0% in type 2 diabetes patients. Not FDA-approved; available for research use only.
This product is intended strictly for laboratory research purposes only. It is not approved for human or animal use and must not be used in food, supplements, pharmaceuticals, or cosmetic applications.
Access is restricted to individuals 21 years of age or older.
